Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention

Area of Science:

• Cardiology
• Neurology
• Thrombosis Research

Background:

• Atrial fibrillation (AF) is a prevalent cardiac arrhythmia linked to a sixfold higher stroke risk.
• Established evidence from randomized trials guides antithrombotic prophylaxis strategies for stroke prevention in AF patients.

Purpose of the Study:

• To review the evidence for antithrombotic prophylaxis in atrial fibrillation.
• To highlight the role of risk stratification in optimizing stroke prevention strategies.

Main Methods:

• Systematic review of published randomized trials on anticoagulants and antiplatelet agents for stroke prevention in atrial fibrillation.
• Analysis of warfarin and aspirin efficacy compared to placebo and each other.
• Discussion of risk stratification tools and their impact on treatment decisions.

Main Results:

• Adjusted-dose warfarin reduces stroke risk by ~60% vs. placebo and ~40% vs. aspirin.
• Aspirin reduces stroke risk by ~20% vs. placebo, primarily for nondisabling strokes.
• Warfarin is most effective at international normalized ratios of 2.0 to 3.0; risk stratification identifies patients who benefit most.

Conclusions:

• Anticoagulation, particularly warfarin, is crucial for stroke prevention in high-risk atrial fibrillation patients, including the elderly.
• Risk stratification is essential to tailor antithrombotic therapy, balancing benefits and risks.
• Understanding AF epidemiology and therapeutic options is key to maximizing stroke prevention.